In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
The in vitro susceptibilities of 10 strains of Chlamydia pneumoniae to a new 8-methoxyquinolone, BAY 12-8039, and to ofloxacin, doxycycline, and erythromycin were determined. The activity of BAY 12-8039 was similar to that of ofloxacin, with a MIC at which 90% of the isolates had no inclusions and a minimal chlamydicidal concentration at which 90% of the isolates had no inclusions after passage of 1.0 microg/ml, but this activity was less than those of doxycycline and erythromycin.
Roblin
P M
PM
Department of Pediatrics, State University of New York, Health Science Center at Brooklyn, 11203, USA.
Hammerschlag
M R
MR
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D002690:Chlamydia Infections / Q000382:microbiology; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D004318:Doxycycline / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D015242:Ofloxacin / Q000494:pharmacology; D011804:Quinolines; D015363:Quinolones / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015363:Quinolones; D004917:Erythromycin; D015242:Ofloxacin; D004318:Doxycycline; D000077266:Moxifloxacin